AchieveRx Quit Co
AchieveRx Quit Co (ACHV) Covered Calls
AchieveRx Quit Co trades in the Biotechnology industry with an IV Rank of 18.65%, low versus the past year. ACHV's highest covered call setup is the $7.50 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 10.62% out of the money with 7 days to expiration, a 12.09% return until expiration, and a 630.64% theoretical annualized return. Across the setups shown, annualized returns run from 42.87% to 630.64% at strikes between $7.50 and $12.50, with 7 to 308 days to expiration, as of Nov 13, 2026.
Read more
Running ACHV covered calls helps you generate income from AchieveRx Quit Co shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ACHV covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ACHV stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ACHV covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ACHV covered call is worth writing.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
| 2026-11-20 | 7 | 7.50 | 10.62 | 0.10 | 0.85 | 82.00 | 12.09 | 630.64 | -1.47 | +0.41 | 242 | 0.75 |
| 2027-03-19 | 126 | 12.50 | 84.37 | 0.05 | 1.40 | 577.00 | 85.10 | 246.53 | -0.74 | +0.32 | 34 | 1.35 |
| 2027-03-19 | 126 | 10.00 | 47.49 | 0.50 | 1.00 | 372.00 | 54.87 | 158.94 | -7.37 | +0.37 | 1,204 | 0.50 |
| 2027-01-15 | 63 | 7.50 | 10.62 | 0.60 | 1.25 | 132.00 | 19.47 | 112.80 | -8.85 | +0.50 | 1,139 | 0.65 |
| 2027-09-17 | 308 | 12.50 | 84.37 | 0.20 | 5.00 | 592.00 | 87.32 | 103.47 | -2.95 | +0.62 | 0 | 4.80 |
| 2027-03-19 | 126 | 7.50 | 10.62 | 1.00 | 2.50 | 172.00 | 25.37 | 73.49 | -14.75 | +0.60 | 567 | 1.50 |
| 2027-06-17 | 216 | 7.50 | 10.62 | 1.00 | 2.55 | 172.00 | 25.37 | 42.87 | -14.75 | +0.61 | 106 | 1.55 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank18.65% Low
- Market cap (M$)698
- 52 weeks high-21.53%
- 52 weeks low158.78%
- Analyst recommendationStrong Buy
1.00 - Target price$14.58
115.04% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-10
- P/E—
- Future P/E—
- EPS (ttm)-1.55
- EPS growth next 5 years—
As of Nov 16, 2026